Corpath Precise Trial

The pivotal, multi-center PRECISE trial demonstrated the safety and feasibility of the remote-controlled CorPath 200 System for use during PCI. The study met its clinical and technical endpoints, with the operator experiencing a significant reduction in radiation exposure. There were no reports of device-related complications and an overall clinical success rate of 97.6%. The average radiation exposure to the interventional cardiologist decreased by 95.2%, in contrast to levels reported during standard interventions.